Kala Pharmaceuticals logo
Kala Pharmaceuticals KALA
$ 2.73 -9.6%
report update icon

Quarterly report 2026-Q2
added 08-19-2026

Kala Pharmaceuticals Interest Expense | KALA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.
Includes:
  • Interest on bank loans
  • Interest on corporate bonds
  • Interest on leases
  • Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Kala Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
5.15 M - 5.81 M 7.27 M 8.38 M 8.59 M 8.48 M 3.31 M 1.02 M 767 K 604 K - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
8.59 M 604 K 4.94 M

Quarterly Interest Expense Kala Pharmaceuticals

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- 107 K - -112 K - - - - - 1.46 M - -2.16 M -119 K 1.47 M - 1.45 M 2.21 M 2.04 M - 2.07 M 2.09 M 2.14 M - 2.16 M 2.13 M 2.13 M - 2.18 M 2.06 M 2.09 M - 432 K 414 K 367 K - 212 K 208 K 198 K - 186 K 186 K - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
2.21 M -2.16 M 1.06 M

Interest Expense of other stocks in the Biotechnology industry

Issuer Interest Expense Price % 24h Market Cap Country
Kodiak Sciences Kodiak Sciences
KOD
13 K $ 97.05 -0.87 % $ 5.16 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
152 K $ 0.02 -56.5 % $ 219 usaUSA
FSD Pharma FSD Pharma
HUGE
9.34 K - 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
225 K $ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
25.7 M - - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
-284 K $ 28.91 -8.89 % $ 1.39 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
-1.5 M $ 13.01 0.74 % $ 1.16 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-12 K - 1052.0 % $ 415 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
15.8 K - - $ 374 usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
51 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
29.5 M - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-5.79 M - 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
48 K - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
1.44 M - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-133 K - - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
1.24 M - - $ 269 M usaUSA
AVROBIO AVROBIO
AVRO
-119 K - 1083.1 % $ 745 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-93 K - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-42.6 M - 0.49 % $ 251 B cayman-islandsCayman-islands
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
11.8 M $ 0.23 -12.11 % $ 16.8 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
7.16 M - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
661 K - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-145 K - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
31 K - -5.98 % $ 34.1 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
-8.33 K - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
41 K - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-127 K - - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
3.49 M - - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
2.37 M - 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
390 K - 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
8.76 M - - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
1.18 M - 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
10.2 M - - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
5.23 M - - $ 528 M usaUSA
Galecto Galecto
GLTO
1.17 M - - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
651 K - 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
268 K - -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
11.4 M - -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
263 K - 1.35 % $ 17.8 M chinaChina
Novavax Novavax
NVAX
40.6 M $ 7.47 -3.24 % $ 1.21 B usaUSA
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
9.46 K - -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
27.1 K - - $ 18.8 M usaUSA
IMARA IMARA
IMRA
-49 K - 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
8.56 M - - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
1.5 M - -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
1.55 M - - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
9.16 K - - $ 63.4 M usaUSA